BofA raised the firm’s price target on HCA Healthcare (HCA) to $470 from $430 and keeps a Neutral rating on the shares after “yet another beat on margins” in what the firm calls a “strong” quarterly report. The firm applies a higher multiple given the outperformance, but thinks that legislative headwinds limit upside, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $490 from $380 at TD Cowen
- HCA Healthcare price target raised to $494 from $445 at Barclays
- HCA Healthcare price target raised to $525 from $495 at UBS
- HCA Healthcare price target raised to $520 from $470 at Goldman Sachs
- HCA Healthcare price target raised to $425 from $400 at Morgan Stanley